Ausgabe 2/2014
Inhalt (14 Artikel)
Acute Leukemias (F Ravandi, Section Editor)
Recent Discoveries in Molecular Characterization of Acute Myeloid Leukemia
Mohamad K. Khasawneh, Omar Abdel-Wahab
Acute Leukemias (F Ravandi, Section Editor)
Frontline Therapy of AML: Should the Older Patient be Treated Differently?
James M. Foran
Acute Leukemias (F Ravandi, Section Editor)
Novel Therapeutics in Acute Myeloid Leukemia
Kendra Sweet, Jeffrey E. Lancet
Acute Leukemias (F Ravandi, Section Editor)
Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?
Heiko Konig, Mark Levis
ACUTE LEUKEMIAS (F RAVANDI, SECTION EDITOR)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Are We Closer to Knowing Who Needs It?
Lazaros J. Lekakis, Brenda W. Cooper, Marcos G. de Lima
Acute Leukemias (F Ravandi, Section Editor)
What is the Standard Regimen for Patients with Acute Promyelocytic Leukemia?
Francesco Lo-Coco, Laura Cicconi
Acute Leukemias (F Ravandi, Section Editor)
Incorporating Tyrosine Kinase Inhibitors into Treatment Regimens for AML and ALL: Is There a Right or Wrong Way?
Farhad Ravandi
Acute Leukemias (R Stone, Section Editor)
The Use of Molecular Genetics to Refine Prognosis in Acute Myeloid Leukemia
Bhavana Bhatnagar, Ramiro Garzon
ACUTE LEUKEMIAS (R STONE, SECTION EDITOR)
Pediatric-Like Therapy for Adults with ALL
Hervé Dombret, Thomas Cluzeau, Françoise Huguet, Nicolas Boissel
ACUTE LEUKEMIAS (R STONE, SECTION EDITOR)
Novel Antibody Therapy in Acute Lymphoblastic Leukemia
Samith T. Kochuparambil, Mark R. Litzow
Acute Leukemias (R Stone, Section Editor)
FLT3 Inhibitors in AML: Are We There Yet?
Akshay Sudhindra, Catherine Choy Smith
Acute Leukemias (R Stone, Section Editor)
Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Amir T. Fathi, Yi-Bin Chen
Acute Leukemias (R Stone, Section Editor)
Contemporary Treatment of APL
Elizabeth H. Cull, Jessica K. Altman